77 related articles for article (PubMed ID: 22366043)
1. Increased numbers but functional defects of CD56+CD3+ cells in lung cancer.
Al Omar SY; Marshall E; Middleton D; Christmas SE
Int Immunol; 2012 Jul; 24(7):409-15. PubMed ID: 22366043
[TBL] [Abstract][Full Text] [Related]
2. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
3. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
4. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
Bamias A; Tsiatas ML; Kafantari E; Liakou C; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Tsitsilonis O; Bamia C; Papatheodoridis G; Politi E; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425
[TBL] [Abstract][Full Text] [Related]
5. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
6. Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by gamma-interferon enhances spontaneous and bispecific anti-CD3 x antitumor antibody-directed lymphokine activated killer cell cytotoxicity.
Azuma A; Yagita H; Matsuda H; Okumura K; Niitani H
Cancer Res; 1992 Sep; 52(18):4890-4. PubMed ID: 1381273
[TBL] [Abstract][Full Text] [Related]
7. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells.
Carrega P; Morandi B; Costa R; Frumento G; Forte G; Altavilla G; Ratto GB; Mingari MC; Moretta L; Ferlazzo G
Cancer; 2008 Feb; 112(4):863-75. PubMed ID: 18203207
[TBL] [Abstract][Full Text] [Related]
8. Impaired zeta chain expression and IFN-gamma production in peripheral blood T and NK cells of patients with advanced lung cancer.
Ciszak L; Kosmaczewska A; Werynska B; Szteblich A; Jankowska R; Frydecka I
Oncol Rep; 2009 Jan; 21(1):173-84. PubMed ID: 19082459
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
[TBL] [Abstract][Full Text] [Related]
10. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases.
Gulubova M; Manolova I; Kyurkchiev D; Julianov A; Altunkova I
APMIS; 2009 Dec; 117(12):870-9. PubMed ID: 20078551
[TBL] [Abstract][Full Text] [Related]
11. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer.
Yazawa T; Kamma H; Fujiwara M; Matsui M; Horiguchi H; Satoh H; Fujimoto M; Yokoyama K; Ogata T
J Pathol; 1999 Jan; 187(2):191-9. PubMed ID: 10365094
[TBL] [Abstract][Full Text] [Related]
12. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
13. Anti-survivin antibody responses in lung cancer.
Karanikas V; Khalil S; Kerenidi T; Gourgoulianis KI; Germenis AE
Cancer Lett; 2009 Sep; 282(2):159-66. PubMed ID: 19380192
[TBL] [Abstract][Full Text] [Related]
14. Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
Yuen MF; Norris S
Clin Immunol; 2001 Dec; 101(3):264-9. PubMed ID: 11726217
[TBL] [Abstract][Full Text] [Related]
15. Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro.
Kelly-Rogers J; Madrigal-Estebas L; O'Connor T; Doherty DG
Hum Immunol; 2006 Nov; 67(11):863-73. PubMed ID: 17145366
[TBL] [Abstract][Full Text] [Related]
16. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC).
Erfani N; Mehrabadi SM; Ghayumi MA; Haghshenas MR; Mojtahedi Z; Ghaderi A; Amani D
Lung Cancer; 2012 Aug; 77(2):306-11. PubMed ID: 22608141
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of immunomagnetic methods used for separation of human natural killer cells from peripheral blood.
Øren A; Husebø C; Iversen AC; Austgulen R
J Immunol Methods; 2005 Aug; 303(1-2):1-10. PubMed ID: 16054641
[TBL] [Abstract][Full Text] [Related]
18. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis.
Chen X; Woiciechowsky A; Raffegerst S; Schendel D; Kolb HJ; Roskrow M
Br J Haematol; 2000 Dec; 111(3):817-25. PubMed ID: 11122143
[TBL] [Abstract][Full Text] [Related]
19. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.
Okita R; Saeki T; Takashima S; Yamaguchi Y; Toge T
Oncol Rep; 2005 Nov; 14(5):1269-73. PubMed ID: 16211295
[TBL] [Abstract][Full Text] [Related]
20. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
